Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)
Japan · Delayed Price · Currency is JPY 1,092.00
-13.00 (-1.18%)
Jun 4, 2026, 3:30 PM JST
TYO:2395 Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 4,567 | 6,013 | 6,974 | 7,759 | 8,183 |
Depreciation & Amortization | 3,432 | 2,610 | 1,867 | 1,600 | 1,177 |
Loss (Gain) From Sale of Assets | 436.85 | 306 | 84 | 56 | 246 |
Asset Writedown & Restructuring Costs | 11.6 | - | - | - | - |
Loss (Gain) From Sale of Investments | 3 | 147 | 31 | 1,321 | -1,058 |
Loss (Gain) on Equity Investments | -2,780 | -3,513 | -2,751 | -2,489 | -1,439 |
Other Operating Activities | 1,894 | 350 | 1,048 | 256 | -90 |
Change in Accounts Receivable | -596.73 | -870 | -956 | -937 | -480 |
Change in Inventory | -2,408 | -149 | -5,003 | -968 | -371 |
Change in Accounts Payable | -59 | -9 | -177 | -268 | -36 |
Change in Other Net Operating Assets | 3,827 | 2,150 | 989 | -2,326 | -180 |
Operating Cash Flow | 8,327 | 7,035 | 2,106 | 4,004 | 5,952 |
Operating Cash Flow Growth | 18.37% | 234.05% | -47.40% | -32.73% | 25.41% |
Capital Expenditures | -5,174 | -10,853 | -8,582 | -4,838 | -1,542 |
Sale of Property, Plant & Equipment | 40.62 | 4 | 5 | 11 | - |
Cash Acquisitions | - | - | -883 | -1,937 | 58 |
Divestitures | - | - | - | - | 1,142 |
Sale (Purchase) of Intangibles | -162.16 | -79 | -22 | -116 | -71 |
Investment in Securities | -1,501 | -771 | 2,625 | 1,018 | -4,194 |
Other Investing Activities | 5.95 | 8 | -50 | -68 | 2 |
Investing Cash Flow | -6,791 | -11,691 | -6,907 | -5,930 | -4,268 |
Short-Term Debt Issued | 6,200 | 2,916 | - | 4,083 | - |
Long-Term Debt Issued | 10,000 | 14,000 | 17,700 | 10,300 | - |
Total Debt Issued | 16,200 | 16,916 | 17,700 | 14,383 | - |
Short-Term Debt Repaid | - | - | -3,903 | - | -6 |
Long-Term Debt Repaid | -9,602 | -8,827 | -6,231 | -5,469 | -3,492 |
Total Debt Repaid | -9,602 | -8,827 | -10,134 | -5,469 | -3,498 |
Net Debt Issued (Repaid) | 6,598 | 8,089 | 7,566 | 8,914 | -3,498 |
Repurchase of Common Stock | -0.03 | - | - | - | - |
Common Dividends Paid | -2,084 | -2,100 | -2,073 | -2,485 | -827 |
Other Financing Activities | -0 | -75 | -175 | -163 | -586 |
Financing Cash Flow | 4,514 | 5,914 | 5,318 | 6,266 | -4,911 |
Foreign Exchange Rate Adjustments | -476.71 | 369 | 559 | 311 | 496 |
Miscellaneous Cash Flow Adjustments | - | -58 | 1 | -2 | - |
Net Cash Flow | 5,574 | 1,569 | 1,077 | 4,649 | -2,731 |
Free Cash Flow | 3,153 | -3,818 | -6,476 | -834 | 4,410 |
Free Cash Flow Growth | - | - | - | - | 19.87% |
Free Cash Flow Margin | 9.69% | -11.78% | -24.48% | -3.32% | 24.85% |
Free Cash Flow Per Share | 75.74 | -91.71 | -155.56 | -20.03 | 105.93 |
Cash Interest Paid | 207.28 | 216 | 125 | 118 | 118 |
Cash Income Tax Paid | 2,175 | 2,013 | 1,223 | 1,437 | 1,014 |
Levered Free Cash Flow | -1,796 | -5,525 | -7,430 | -2,725 | 2,467 |
Unlevered Free Cash Flow | -1,613 | -5,398 | -7,344 | -2,647 | 2,546 |
Change in Working Capital | 762.72 | 1,122 | -5,147 | -4,499 | -1,067 |